Stem Cell Therapy for Ischemic Heart Disease: Current Evidence
Stem cell therapy for ischemic heart disease (IHD) shows promise in improving cardiac function and reducing mortality in the long term, but clinical outcomes remain modest and the therapy is not yet ready for routine clinical use outside of research protocols. 1
Current State of Evidence
The ESC Working Group on Cellular Biology of the Heart (2019) provides the most authoritative guidance, acknowledging that despite major advances in cell source and delivery methods, clinical outcomes remain unsatisfactory with major obstacles including low engraftment rates (less than 1% long-term retention) and poor cell survival in the hostile post-infarction environment 1. The consensus statement from Circulation (2017) similarly notes that functional improvements cannot be explained solely by new cardiomyocyte formation, which occurs at very low rates 2.
What the Evidence Shows
Mortality and Morbidity Benefits
- Long-term mortality reduction: Bone marrow-derived stem cell (BMSC) therapy reduces mortality at ≥12 months follow-up (RR 0.42,95% CI 0.21-0.87), though this is low-quality evidence 3
- Non-fatal MI reduction: Decreased incidence (RR 0.38,95% CI 0.15-0.97) 3
- Arrhythmia reduction: Lower incidence (RR 0.42,95% CI 0.18-0.99) 3
- No clear short-term mortality benefit: Effects at <12 months are uncertain 3
Functional Improvements
The most recent meta-analysis (2026) demonstrates:
- Overall LVEF improvement of 3.3%, with better results in chronic IHD (8.2%) and heart failure (5.3%) compared to acute MI (2.7%) 4
- Dose-response relationship: 2% LVEF increase per 10⁹ cells infused 4
- NYHA functional class improvement: Significant reduction from baseline (2.6) to 6 months (1.8) and 12 months (1.9) in heart failure patients 4
Cell Types and Delivery Methods
Bone marrow-derived cells remain the most studied first-generation therapy, with mesenchymal cells showing promise in phase 3 trials 2. However, the ESC position paper emphasizes that traditional delivery methods (intracoronary, intramyocardial injection) result in poor retention, with approximately 35% of cells localizing to the lungs due to venous drainage 1.
Pluripotent stem cells (embryonic or induced pluripotent) can differentiate into cardiomyocytes with >80% efficiency in vitro and successfully engraft in immunosuppressed animals, but carry teratoma risk if undifferentiated cells remain 2.
Critical Limitations and Pitfalls
Major Obstacles
- Cell retention crisis: Long-term engraftment <1% regardless of cell dose or type 1
- Mechanism uncertainty: Benefits likely derive from paracrine effects, angiogenesis, and anti-inflammatory actions rather than true cardiac regeneration 2, 1
- Publication bias: Study heterogeneity and evidence of publication bias compromise evidence quality 4
- Low event rates: Imprecision in mortality and morbidity outcomes due to small numbers 3
Safety Considerations
- Periprocedural adverse events are infrequent across multiple trials 3
- No long-term adverse events reported in systematic reviews 5
- Teratoma risk with pluripotent cells requires complete differentiation before transplantation 2
Emerging Strategies to Improve Outcomes
The ESC Working Group (2019) recommends tissue engineering approaches combining cells with biomaterials (hydrogels, cell sheets, injectable matrices) to enhance retention, with some methods achieving >80% long-term retention 1. Cell sheet transplantation specifically shows promise with cardiac-related readmission rates of 0-30.4% and no cardiac-related deaths reported 6.
Clinical Recommendation
Do not offer stem cell therapy for IHD outside of well-designed clinical trials. While the therapy appears safe and shows modest functional improvements with potential long-term mortality benefits, the evidence quality is low, mechanisms remain unclear, and the therapy has not achieved sufficient efficacy for routine clinical implementation 1.
If considering enrollment in trials, prioritize:
- Chronic IHD or heart failure patients (better outcomes than acute MI) 4
- Protocols using tissue engineering/biomaterial delivery systems (improved retention) 1
- Studies with adequate cell dosing (≥100 × 10⁶ cells) 4
- Long-term follow-up protocols (benefits emerge after 12 months) 3
The field requires further research addressing cell retention, optimal delivery methods, patient selection criteria, and clarification of therapeutic mechanisms before clinical translation can be recommended 2, 1.